ACLX
Arcellx Inc
$
71.310
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
71.570
Open
70.690
VWAP
70.77
Vol
340.05K
Mkt Cap
3.93B
Low
69.505
Amount
24.06M
EV/EBITDA(TTM)
--
Total Shares
53.50M
EV
3.39B
EV/OCF(TTM)
--
P/S(TTM)
50.31
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
13.92M
-49.15%
-1.032
+102.37%
13.71M
-47.33%
-1.024
+113.32%
26.26M
+71.99%
-0.837
-3.77%
Estimates Revision
The market is revising Downward the revenue expectations for Arcellx, Inc. (ACLX) for FY2025, with the revenue forecasts being adjusted by -27.64% over the past three months. During the same period, the stock price has changed by 10.47%.
Revenue Estimates for FY2025
Revise Downward
-27.64%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+32.49%
In Past 3 Month
Stock Price
Go Up
+10.47%
In Past 3 Month
15 Analyst Rating
55.66% Upside
Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 111.00 USD with a low forecast of 93.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
0 Hold
0 Sell
Strong Buy
55.66% Upside
Current: 71.310
Low
93.00
Averages
111.00
High
121.00
55.66% Upside
Current: 71.310
Low
93.00
Averages
111.00
High
121.00
Citi
initiated
$110
2025-06-18
Reason
Citi
Price Target
$110
2025-06-18
initiated
Reason
Scotiabank
Outperform -> NULL
downgrade
$133 -> $93
2025-05-09
Reason
Scotiabank
Price Target
$133 -> $93
2025-05-09
downgrade
Outperform -> NULL
Reason
Scotiabank lowered the firm's price target on Arcellx to $93 from $133 and keeps an Outperform rating on the shares. While iMMagine-1 results support an ultimately positive trial outcome in end-stage multiple myeloma, changes at Centers for Biologics Evaluation and Research warn of new regulatory risk that has begun and will continue to weigh on the anito-cel regulatory path, the analyst tells investors.
Needham
Gil Blum
Strong Buy
Reiterates
$105
2024-12-10
Reason
Needham
Gil Blum
Price Target
$105
2024-12-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$115
2024-12-10
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$115
2024-12-10
Reiterates
Strong Buy
Reason
UBS
Ashwani Verma
Strong Buy
Maintains
$106 → $114
2024-12-10
Reason
UBS
Ashwani Verma
Price Target
$106 → $114
2024-12-10
Maintains
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$105
2024-12-09
Reason
Needham
Gil Blum
Price Target
$105
2024-12-09
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Arcellx Inc (ACLX.O) is -17.81, compared to its 5-year average forward P/E of -21.18. For a more detailed relative valuation and DCF analysis to assess Arcellx Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-21.18
Current PE
-17.81
Overvalued PE
-6.94
Undervalued PE
-35.42
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-17.97
Current EV/EBITDA
-14.79
Overvalued EV/EBITDA
-6.81
Undervalued EV/EBITDA
-29.14
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
39.34
Current PS
59.58
Overvalued PS
92.15
Undervalued PS
-13.46
Financials
Annual
Quarterly
FY2025Q1
YoY :
-79.29%
8.13M
Total Revenue
FY2025Q1
YoY :
+335.79%
-68.90M
Operating Profit
FY2025Q1
YoY :
+765.10%
-62.27M
Net Income after Tax
FY2025Q1
YoY :
+707.14%
-1.13
EPS - Diluted
FY2025Q1
YoY :
+66.74%
-63.93M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+531.31%
-159.47
FCF Margin - %
FY2025Q1
YoY :
+4076.77%
-766.02
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
973.5K
USD
3
3-6
Months
3.5M
USD
7
6-9
Months
16.2M
USD
23
0-12
Months
5.6M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
369.6K
Volume
2
3-6
Months
291.1K
Volume
2
6-9
Months
1.2M
Volume
5
0-12
Months
0.0
Volume
0
Bought
0-3
1
552.4K
Volume
Months
3-6
2
1.9M
Volume
Months
6-9
3
1.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
973.5K
USD
3
3-6
Months
3.5M
USD
7
6-9
Months
16.2M
USD
23
0-12
Months
5.6M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ACLX News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
09:34:13
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel
2025-02-27 (ET)
2025-02-27
16:04:17
Arcellx reports FY24 EPS ($2.00), consensus ($1.50)
2025-01-03 (ET)
2025-01-03
06:06:43
Opco lists five potential biotech targets into JPMorgan conference
Sign Up For More Events
Sign Up For More Events
News
9.0
06-30BenzingaFDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
4.0
06-17BenzingaCitigroup Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $110
4.0
06-16BenzingaHC Wainwright & Co. Reiterates Buy on Arcellx, Maintains $115 Price Target
Sign Up For More News
People Also Watch
CCOI
Cogent Communications Holdings Inc
48.830
USD
-0.08%
ALKT
Alkami Technology Inc
27.260
USD
-0.58%
ATAT
Atour Lifestyle Holdings Ltd
35.690
USD
+0.03%
TNL
Travel + Leisure Co
63.180
USD
+2.40%
ARLP
Alliance Resource Partners LP
27.980
USD
+0.04%
MWA
Mueller Water Products Inc
25.150
USD
+1.62%
PBF
PBF Energy Inc
24.160
USD
+3.56%
HP
Helmerich and Payne Inc
16.740
USD
-0.48%
GSAT
Globalstar Inc
24.570
USD
-1.44%
RIG
Transocean Ltd
3.000
USD
-2.60%
FAQ
What is Arcellx Inc (ACLX) stock price today?
The current price of ACLX is 71.31 USD — it has increased 1.48 % in the last trading day.
What is Arcellx Inc (ACLX)'s business?
What is the price predicton of ACLX Stock?
What is Arcellx Inc (ACLX)'s revenue for the last quarter?
What is Arcellx Inc (ACLX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Arcellx Inc (ACLX)'s fundamentals?
How many employees does Arcellx Inc (ACLX). have?